In recent years, U.S. courts began to pay attention to the antitrust of generic drugs, and generic drug manufacturers conspired to artificially raise and manipulate the prices of generic drugs sold in various parts of the United States. There have been a number of copycat drug companies sued before, and the number of defendants and drug companies involved in the case is still growing.
In a 606 page state joint action report issued by the District Court of Connecticut on June 10, 51 States and regions required as many as 26 generic companies and 10 heads of pharmaceutical companies to jointly modify the prices of at least 80 skin disease generic drugs. Long term agreements have been reached between manufacturers to ensure each competitor's "fair share" in the market and to prevent "price erosion" caused by competition.
In the defendant's list, we can see the names of some famous pharmaceutical companies - Novartis, TIWA, mylan and Pfizer. Others include Actavis, amneal, Aurobindo, Bausch, fuguera, glenmark, G & W, lannett, Lupin, Mallinckrodt, Perrigo, sun pharmaceutical, taro pharmaceuticals, wockhardt, teligent Pharma, etc.
In a statement, William Tong, the Attorney General of Connecticut, said: the state courts all allege that the executives of these pharmaceutical companies use telephone conversation, SMS, e-mail, meetings and dinner parties to modify and determine the price of generic drugs, reduce competition, and unreasonably restrict the trade of generic drugs sold across the United States, as if it was a standard business model.
The lawsuit lists drugs subject to price manipulation and market distribution agreements, including solutions used to treat various skin conditions, pain and allergies, such as chlorpyridone propionate cream, clomipramine propionate ointment, cefpodoxime axetil tablets, dexamethasone ointment, metronidazole tablets, mometasone furfural ointment, etc. Sales of the 80 local generic drugs in the United States reached billions of dollars. The latest lawsuit requires the defendant company and individual to compensate for the loss and accept civil punishment. Meanwhile, the court will take action to restore the competition in the generic drug market.